Search

Displaying results 7221 - 7230 of 9714 in total
  1. Drug

    Ribociclib

    go.drugbank.com/drugs/DB11730
    ApprovedInvestigational

    Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6).

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index
  2. Drug

    Capmatinib

    go.drugbank.com/drugs/DB11791
    ApprovedInvestigational

    Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades … [A199122] This co-occurrence has made c-Met a desirable target in the treatment of NSCLC.

  3. Drug

    Bictegravir

    go.drugbank.com/drugs/DB11799
    ApprovedInvestigational

    It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet.[L43677] … Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection.

  4. Drug

    Elamipretide

    go.drugbank.com/drugs/DB11981
    ApprovedInvestigational

    [A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane. … Elamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction.

  5. Drug

    Nirogacestat

    go.drugbank.com/drugs/DB12005
    ApprovedInvestigational

    Nirogacestat is a small-molecule gamma-secretase inhibitor that was investigated as a potential treatment for desmoid tumors. … granted breakthrough therapy, fast track, and orphan drug designations for the treatment of desmoid tumors, and the final approval was based on positive results obtained in the Phase 3 DeFi trial, where a

  6. Drug

    Ozagrel

    go.drugbank.com/drugs/DB12017
    Investigational

    Ozagrel has been used in trials studying the treatment of Dry Eye Syndromes.

    Categories: Thromboxane-A Synthase, antagonists & inhibitors
  7. Drug

    Pardoprunox

    go.drugbank.com/drugs/DB12061
    Investigational

    Pardoprunox is a partial dopamine D2 agonist and noradrenergic agonist with serotonin 5-HT1A agonist properties.

  8. Drug

    Iberdomide

    go.drugbank.com/drugs/DB12101
    Investigational

    [L64055] Iberdomide has shown anti-tumor activity in multiple myeloma cells resistant to lenalidomide and pomalidomide, and as a CELMoD is designed to degrade Ikaros and Aiolos more potently than immunomodulatory … accelerated approval on August 13, 2026, in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a

  9. Drug

    Defactinib

    go.drugbank.com/drugs/DB12282
    ApprovedInvestigational

    Defactinib is a small molecule kinase inhibitor targeted against focal adhesion kinase (FAK) and proline-rich tyrosine kinase-2 (Pyk2), the two members of the FAK family of nonreceptor tyrosine kinases … [L53198,L53208] FAK is important for the integrin-mediated activation of several downstream signal transduction pathways, including those involving RAS/MEK/ERK and PI3K/Akt, and its upregulation is a key

  10. Drug

    Doravirine

    go.drugbank.com/drugs/DB12301
    ApprovedInvestigational

    [L12729,L4562] Doravirine is available by itself or as a combination product of doravirine (100 mg), lamivudine (300 mg), and tenofovir disoproxil fumarate (300 mg).